📰 BloombergBloombergCodex · 实盘不做把握 8/10
北京时间·🕒 发布 23:50:14时区推断·⟳ 抓取 23:58:26·⚡ 决策 07-31 23:59:34 +1m08s·88.1 天前
Apnimed美股IPO扩大发行后首日大涨38%
这条信号的核心信息是APMD.US首日交易已经从16美元发行价跳至约22美元开盘，利好已直接体现在当下价格反应中。
📄 原文Bloomberg↗ 原文
Apnimed Inc., a late-stage drug developer focused on sleep apnea, leapt 38% on Friday after raising $192 million in an…
不做 Apnimed（APMD.US）
IPO首日上涨已在报道时发生，且没有FDA获批、销售指引或订单级新增基本面催化；追涨只是追随已兑现的价格反应，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-31 · 扩散 medium · price-in 风险 high ↗
关键理由
- 这条信号的核心信息是APMD.US首日交易已经从16美元发行价跳至约22美元开盘，利好已直接体现在当下价格反应中。
- 公司仍处睡眠呼吸暂停药物Oxnimbi上市申请审评阶段，本文未披露新的FDA获批、销售指引或订单级增量。
- IPO扩大发行和认购需求更多说明生物科技新股发行环境改善，缺少可短周期映射到其它上市公司的确定传导。
主要风险
- IPO首日流动性和换手极不稳定，追涨容易面对高开后回落和无历史成交锚的问题。
- 核心药物仍待FDA审评，本文没有新增临床或监管里程碑来支撑二级市场继续追多。
原文全文
展开原文 · 2,333 字
Apnimed Inc., a late-stage drug developer focused on sleep apnea, leapt 38% on Friday after raising $192 million in an upsized US initial public offering.
Shares of the biotech firm opened at $22 apiece in New York, versus an IPO price of $16. The company sold 12 million shares after marketing 10 million shares for $14 to $16 each. The listing had attracted demand for multiple times the available shares and drawn sizable orders from long-only investors, Bloomberg News reported.
The trading gives the Cambridge, Massachusetts-based firm a market value of about $880 million, based on the outstanding shares listed in its filings with the US Securities and Exchange Commission.
The listing hits the US market following a busy first half of the year for stock sales from drug developers. New entrants in biotech and pharma have raised $5.4 billion so far in 2026, according to data compiled by Bloomberg. That’s up from just $969.2 million from the same period a year prior.
Apnimed is developing an oral tablet, Oxnimbi, to treat obstructive sleep apnea. The firm submitted an application to the US Food and Drug Administration in April to market the drug, according to its filings. The regulatory review is expected to take 10 months from application submission. If approved, Oxnimbi would compete with Eli Lilly & Co.’s Zepbound as the only therapeutics available to treat sleep apnea.
The company’s investors include Morningside Ventures, alternative asset manager Alpha Wave Global and Columbia Management, a unit of Ameriprise Financial Inc. After the offering, Morningside’s stake in the company was expected to fall to 18% from 25% while Alpha Wave was set to have a 19% stake, down from 26%.
Apnimed had net income of $67.7 million on revenue of $84.8 million in the three months ended March 31, compared with a net loss of $28.6 million on revenue of $3.1 million a year earlier, its filings showed.
The offering was led by Bank of America Corp., Evercore Inc., Cantor Fitzgerald and LifeSci Capital. Shares trade on the Nasdaq Global Market under the symbol APMD.
For the latest news on equity capital markets activity in the US, Canada and Latin America, terminal users can follow the channel or visit NI BFWECMUS. To subscribe to ECM Watch, Bloomberg’s daily roundup of news from around the region, click here.
Shares of the biotech firm opened at $22 apiece in New York, versus an IPO price of $16. The company sold 12 million shares after marketing 10 million shares for $14 to $16 each. The listing had attracted demand for multiple times the available shares and drawn sizable orders from long-only investors, Bloomberg News reported.
The trading gives the Cambridge, Massachusetts-based firm a market value of about $880 million, based on the outstanding shares listed in its filings with the US Securities and Exchange Commission.
The listing hits the US market following a busy first half of the year for stock sales from drug developers. New entrants in biotech and pharma have raised $5.4 billion so far in 2026, according to data compiled by Bloomberg. That’s up from just $969.2 million from the same period a year prior.
Apnimed is developing an oral tablet, Oxnimbi, to treat obstructive sleep apnea. The firm submitted an application to the US Food and Drug Administration in April to market the drug, according to its filings. The regulatory review is expected to take 10 months from application submission. If approved, Oxnimbi would compete with Eli Lilly & Co.’s Zepbound as the only therapeutics available to treat sleep apnea.
The company’s investors include Morningside Ventures, alternative asset manager Alpha Wave Global and Columbia Management, a unit of Ameriprise Financial Inc. After the offering, Morningside’s stake in the company was expected to fall to 18% from 25% while Alpha Wave was set to have a 19% stake, down from 26%.
Apnimed had net income of $67.7 million on revenue of $84.8 million in the three months ended March 31, compared with a net loss of $28.6 million on revenue of $3.1 million a year earlier, its filings showed.
The offering was led by Bank of America Corp., Evercore Inc., Cantor Fitzgerald and LifeSci Capital. Shares trade on the Nasdaq Global Market under the symbol APMD.
For the latest news on equity capital markets activity in the US, Canada and Latin America, terminal users can follow the channel or visit NI BFWECMUS. To subscribe to ECM Watch, Bloomberg’s daily roundup of news from around the region, click here.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。